NS Partners Ltd grew its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 1.2% during the 1st quarter, HoldingsChannel reports. The fund owned 72,842 shares of the medical instruments supplier’s stock after acquiring an additional 878 shares during the quarter. Becton Dickinson and makes up 1.7% of NS Partners Ltd’s investment portfolio, making the stock its 21st biggest position. NS Partners Ltd’s holdings in Becton Dickinson and were worth $18,191,000 at the end of the most recent quarter.
Several other hedge funds have also bought and sold shares of BDX. Oregon Public Employees Retirement Fund raised its stake in shares of Becton Dickinson and by 22,485.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 6,545,502 shares in the last quarter. Ronna Sue Cohen raised its stake in shares of Becton Dickinson and by 24,129.0% during the first quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock worth $5,734,000 after acquiring an additional 5,710,365 shares in the last quarter. Norges Bank purchased a new position in shares of Becton Dickinson and during the fourth quarter worth approximately $515,703,000. Mackenzie Financial Corp raised its stake in shares of Becton Dickinson and by 27.7% during the fourth quarter. Mackenzie Financial Corp now owns 1,943,752 shares of the medical instruments supplier’s stock worth $437,966,000 after acquiring an additional 421,825 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Becton Dickinson and by 10.4% during the first quarter. JPMorgan Chase & Co. now owns 4,418,870 shares of the medical instruments supplier’s stock worth $1,103,526,000 after acquiring an additional 416,459 shares in the last quarter. 84.03% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts have recently issued reports on BDX shares. KeyCorp restated an “overweight” rating and issued a $262.00 target price (down previously from $273.00) on shares of Becton Dickinson and in a report on Friday, May 10th. Zacks Investment Research upgraded shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a report on Wednesday, April 10th. Raymond James cut their target price on shares of Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating on the stock in a report on Tuesday, March 19th. Piper Jaffray Companies raised their target price on shares of Becton Dickinson and to $274.00 and gave the stock an “overweight” rating in a report on Tuesday, February 5th. Finally, BMO Capital Markets cut their target price on shares of Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating on the stock in a report on Friday, May 10th. Six analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Becton Dickinson and currently has an average rating of “Buy” and a consensus target price of $255.31.
In related news, CEO Vincent A. Forlenza sold 11,340 shares of Becton Dickinson and stock in a transaction on Monday, February 25th. The shares were sold at an average price of $250.40, for a total value of $2,839,536.00. Following the sale, the chief executive officer now owns 227,250 shares in the company, valued at $56,903,400. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Vincent A. Forlenza sold 3,123 shares of Becton Dickinson and stock in a transaction on Monday, March 4th. The shares were sold at an average price of $255.03, for a total transaction of $796,458.69. Following the completion of the sale, the chief executive officer now owns 215,372 shares in the company, valued at approximately $54,926,321.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 47,469 shares of company stock worth $11,675,851. 0.12% of the stock is currently owned by company insiders.
Shares of Becton Dickinson and stock opened at $235.19 on Friday. The company has a current ratio of 0.96, a quick ratio of 0.59 and a debt-to-equity ratio of 0.82. Becton Dickinson and Co has a 52-week low of $208.62 and a 52-week high of $265.87. The company has a market capitalization of $63.11 billion, a PE ratio of 21.36, a PEG ratio of 1.75 and a beta of 1.16.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. The business had revenue of $4.20 billion for the quarter, compared to analysts’ expectations of $4.25 billion. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The firm’s revenue for the quarter was down .6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.65 earnings per share. As a group, analysts predict that Becton Dickinson and Co will post 11.7 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Friday, June 7th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 1.31%. The ex-dividend date is Thursday, June 6th. Becton Dickinson and’s dividend payout ratio (DPR) is currently 27.97%.
TRADEMARK VIOLATION WARNING: “Becton Dickinson and Co (BDX) Position Raised by NS Partners Ltd” was first published by Stock Observer and is owned by of Stock Observer. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.thestockobserver.com/2019/05/25/becton-dickinson-and-co-bdx-position-raised-by-ns-partners-ltd.html.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Recommended Story: Consumer behavior in bull markets
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.